| Outcome Measures: |
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12), SVR12 was defined as hepatitis C virus (HCV) ribonucleic acid (RNA) lower than the limit of quantification (LLoQ) 12 weeks after completing study therapy. HCV RNA was measured using the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0®, which has a LLoQ of 15 IU/mL., Week 24 (Immediate Treatment + Intensive PK) or Week 40 (Deferred Treatment)|Number of Participants Experiencing an Adverse Event (AE) During the Initial Treatment and 14-day Follow-up Periods, An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. This analysis includes the Immediate Treatment + Intensive PK group and the placebo treatment period for the Deferred Treatment group., Up to Week 14|Number of Participants Discontinuing Study Drug Due to AEs During the Initial Treatment Period, An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. This analysis includes the Immediate Treatment + Intensive PK group and the placebo treatment period for the Deferred Treatment group., Up to Week 12 | Secondary: Percentage of Participants With Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24), SVR24 was defined as HCV RNA \<LLoQ 24 weeks after completing study therapy. HCV RNA was measured using the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0®, which has a LLoQ of 15 IU/mL., Week 36 (Immediate Treatment + Intensive PK) or Week 52 (Deferred Treatment)|Percentage of Participants With Sustained Virologic Response 4 Weeks After Completing Study Therapy (SVR4), SVR4 was defined as HCV RNA \<LLoQ 4 weeks after completing study therapy. HCV RNA was measured using the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0®, which has a LLoQ of 15 IU/mL., Week 16 (Immediate Treatment + Intensive PK) or Week 32 (Deferred Treatment)
|
